Personalized Medicine Genomas specializes in clinical pharmacogenetic testing to tailor prescription and dosing of a wide range of medications, presenting a compelling opportunity to expand pharmacogenomics testing partnerships and integrate with healthcare providers seeking personalized treatment strategies.

Strategic Acquisition As a former independent entity now under Rennova Health, Genomas may offer cross-selling opportunities with Rennova’s diagnostics and software solutions, enabling bundled services and expanded reach within the healthcare provider network.

Small Middle Market With a lean team and limited revenue, Genomas represents a high-potential target for growth services, including sales acceleration, channel partnerships, and enterprise software solutions to scale operations and improve data management.

Public Market Link Being associated with a publicly traded parent (RNVA) could simplify due diligence and fundraising, making it feasible to propose joint ventures, pilots, or research collaborations that leverage public market credibility.

Tech Stack Fit Existing technology usage (AWS, React, Microsoft 365, Bootstrap) suggests openness to cloud-based data integration, analytics, and clinician-facing dashboards, offering cross-sell opportunities for software enhancements and secure data workflows.